Cargando…

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

The value of measuring IGF1 bioactivity in active acromegaly is unknown. Soluble Klotho (S-Klotho) level is elevated in active acromegaly and it has been suggested that S-Klotho can inhibit activation of the IGF1 receptor (IGF1R). A cross-sectional study was carried out in 15 patients with active ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varewijck, A J, van der Lely, A J, Neggers, S J C M M, Lamberts, S W J, Hofland, L J, Janssen, J A M J L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001616/ https://www.ncbi.nlm.nih.gov/pubmed/24692508 http://dx.doi.org/10.1530/EC-14-0028

Ejemplares similares

Soluble Klotho: a possible predictor of quality of life in acromegaly patients
por: Coopmans, Eva C., et al.
Publicado: (2020)

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
por: Varewijck, A. J., et al.
Publicado: (2012)

Pregnancy and acromegaly
por: Muhammad, Ammar, et al.
Publicado: (2016)

Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenarians’ offspring
por: Vitale, Giovanni, et al.
Publicado: (2012)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Approach to the Patient With Treatment-resistant Acromegaly
por: Coopmans, Eva C, et al.
Publicado: (2022)

IGF-I Bioactivity in an Elderly Population: Relation to Insulin Sensitivity, Insulin Levels, and the Metabolic Syndrome
por: Brugts, Michael P., et al.
Publicado: (2010)

IGF-IR Targeted Therapy: Past, Present and Future
por: Janssen, Joseph A. M. J. L., et al.
Publicado: (2014)

The position of combined medical treatment in acromegaly
por: Coopmans, Eva C., et al.
Publicado: (2019)

Soluble Klotho protein as a novel serum biomarker in patients with acromegaly
por: Dąbrowska, Anna M., et al.
Publicado: (2014)

MON-327 Soluble Alpha Klotho and IGF-I Before Surgery as Prognostic Factors to Acromegaly Long-term Remission
por: de Oliveira Longo Schweizer, Junia Ribeiro, et al.
Publicado: (2020)

Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity
por: Schweizer, Júnia R O L, et al.
Publicado: (2021)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Towards an Earlier Diagnosis of Acromegaly and Gigantism
por: Sisco, Jill, et al.
Publicado: (2021)

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
por: Vila, Greisa, et al.
Publicado: (2020)

Potency of Full- Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations
por: Janssen, Joseph A. M. J. L., et al.
Publicado: (2016)

Clinical, quality of life, and economic value of acromegaly disease control
por: Ben-Shlomo, A., et al.
Publicado: (2011)

A consensus on the diagnosis and treatment of acromegaly complications
por: Melmed, S., et al.
Publicado: (2012)

Insulin Analogs and Cancer: A Note of Caution
por: Janssen, Joseph A. M. J. L., et al.
Publicado: (2014)

ACRODAT® and AcroVoice: an insight into a holistic approach to the management of acromegaly
por: Lundie, Mark, et al.
Publicado: (2019)

The effects of aerobic and anaerobic exercises on circulating soluble-Klotho and IGF-I in young and elderly adults and in CAD patients
por: Saghiv, Moran S, et al.
Publicado: (2017)

OR32-2 Alpha Klotho as a Marker of Disease Activity in Acromegaly
por: Schweizer, Junia, et al.
Publicado: (2019)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
por: Geraedts, Victor J., et al.
Publicado: (2017)

Performance of soluble Klotho assays in clinical samples of kidney disease
por: Neyra, Javier A, et al.
Publicado: (2019)

Aging and sex affect soluble alpha klotho levels in bonobos and chimpanzees
por: Behringer, V., et al.
Publicado: (2018)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Differences in quality of life between genders in acromegaly
por: Ballesteros‐Herrera, Daniel, et al.
Publicado: (2021)

Executive functioning and quality of life in acromegaly
por: Solomon, Emilia, et al.
Publicado: (2019)

Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly
por: Langlois, Fabienne, et al.
Publicado: (2020)

Future treatment strategies of aggressive pituitary tumors
por: Lamberts, Steven W. J., et al.
Publicado: (2008)

Klotho is upregulated in human cardiomyopathy independently of circulating Klotho levels
por: Poelzl, G., et al.
Publicado: (2018)

New Insights into the Mechanism of Action of Soluble Klotho
por: Dalton, George D., et al.
Publicado: (2017)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients
por: Buiten, Maurits S, et al.
Publicado: (2014)

Acromegaly Quality of Life Questionnaire (AcroQoL)
por: Badia, Xavier, et al.
Publicado: (2004)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_82arfb5p8gi66g4qha4vja1aor